Spectrum Pharmaceuticals announces submission to FDA of updated BLA for ROLONTIS

This article was originally published here

The BLA for ROLONTIS is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in

The post Spectrum Pharmaceuticals announces submission to FDA of updated BLA for ROLONTIS appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply